Intrinsiqq
Forte Biosciences, Inc. logo

Forte Biosciences, Inc. Financials

FBRX

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 11 available years
Income Statement
TTM
DEC 2025
2:1 split
DEC 2024
~4.4:1 split
DEC 2023
2:1 split
DEC 2022
DEC 2021
2:1 split
Revenues
Revenue$0–––––
General & Administrative$1$12$15$11$8$8
Research & Development$3$58$21$22$6$14
Total Operating Expenses$4$71$37$32$14$21
Operating Income-$4-$71-$37-$32-$14-$21
Non-Operating
Net Interest Expense-$4–––––
Other Non-Operating Income (Expense)-$0$2$1-$0-$0-$0
EBT (Earnings Before Tax)–-$68-$35-$31––
Income Tax Expense–$1$0–––
Net Income
Net Income-$29-$69-$35-$31-$14-$22
Per Share Data
Revenue Per Share$0.57–––––
EPS (Basic)-$64.57-$4.71-$12.17-$24.92-$20.00-$38.75
EPS (Diluted)-$64.57-$4.71-$12.17-$24.92-$20.00-$38.75
Weighted Avg Shares (Basic)23.6M–––17.4M14.0M
Weighted Avg Shares (Diluted)23.6M–––17.4M14.0M
Shares Outstanding63,014.45912.9M6.4M1.5M695,341.24558,712.72

Forte Biosciences (FBRX) financials: revenue, profit and margins

Forte Biosciences (FBRX) generated about n/a in revenue and -$88 million in net income over the trailing twelve months, growing at roughly -9.8% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Forte Biosciences profitable?+

Forte Biosciences reported about -$88 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Forte Biosciences growing?+

Forte Biosciences's revenue has compounded at roughly -9.8% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside FBRX's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 7 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 13 Aug 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with FBRX

CompareIntrinsic value
LQDALiquidia Corporation
$54.43-3.88%63
BOLTBolt Biotherapeutics Inc.
$4.91-2.96%15
TBPHTheravance Biopharma Inc.
No recent price82
TXMDTherapeuticsMD, Inc.
$1.71-5.52%29
UPBUpstream Bio, Inc.
$1.59-20.50%21
ATAIAtaiBeckley Inc.
$0.53-25.36%40
STTKShattuck Labs Inc.
$4.46-1.98%25
IMNMImmunome Inc.
$15.68-5.60%10

Held by ETFs

FBRX is in 4 US ETFs. The largest of them, with FBRX's weight in each:

Spot a number that looks wrong? Check it in FBRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing FBRX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.